Sorry, mate. Only reading this now.
Yes it does, and most likely the same company it's doing its comparator study against. Read up on Axogen Inc. and specifically Axoguard. They also have their Avance Nerve Graft product (an allograft product), but this still requires the use of their Axoguard (plus sutures) to encompass both ends of the Avance graft attachement.
Their allograft product’s success rate shows a whopping 52.6% – 86% differential between recovery rates. Better than nothing, but hardly spectacular.
Sorry, mate. Only reading this now. Yes it does, and most likely...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.35M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 35.5¢ | $51.60K | 145.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 145099 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 131882 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |